Comparison of the Effectiveness of L-Carnitine Supplementation on the Weight of Hemodialysis Patients

Comparison of the Effectiveness of L-Carnitine Supplementation on Body Mass Changes in Patients Undergoing Chronic Hemodialysis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200812048380N3

Enrollment

Registered

2025-08-25

Start date

2025-01-20

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia. Muscle wasting and atrophy, not elsewhere classified

Interventions

Intervention 1: Intervention group: Receive two capsules of L-carnitine 1000 mg daily for 8 weeks from Karen Pharmaceutical Company, Iran. Intervention 2: Control group: Received 2 placebo capsules da

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age over 18 and under 65 years Body mass index over 20 and under 30 kilograms per square meter

Exclusion criteria

Exclusion criteria: Pregnancy Having enteral and parenteral nutritional support Consumption of omega-3 supplements and antioxidants Breastfeeding Intention to become pregnant within the next 6 months Infectious diseases Thyroid disorders Thrombocytopenia Dumping syndrome

Design outcomes

Primary

Measure	Time frame
Muscle tone. Timepoint: At the beginning of the study, before the intervention began, and then again 7, 14, and 21 days after the study commenced. Method of measurement: Bioimpedance analysis device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahshad Ghodousi

Tehran University of Medical Sciences

mahshad.ghoddusi@gmail.com+98 21 7745 0199

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026